The Genome Test Overview
Catalyst participants have access to the MyOme Personal Genome Test requested by their provider free-of-cost. This genome sequencing test produces a Proactive Health Report, a pharmacogenomics report and 3 Polygenic Risk Score reports including type 2 diabetes, coronary artery disease, and breast cancer (for biological females). Each clinical report focuses on clinical risk where there is clear actionability and is signed by a certified laboratory director and ready to act on.
MyOme Personal Genome Proactive Health Report
Identifies genetic variants in 81 genes identified by the American College of Medical Genetics and Genomics (ACMG) for their association with cancers, heart disease, metabolic conditions and other health risks, and for their actionability when used for early screening.
MyOme Personal Genome Pharmacogenomic Report
Summarizes known variants in 15 genes associated with response to medications that may provide additional information to help guide drug and treatment selection.
Integrated Personal Risk Score Reports
Provide risk assessments for type 2 diabetes, coronary artery disease, and breast cancer. These reports combine an analysis of your patient’s genome coupled with clinical risk factors to provide a personal risk score for each condition.
Read more about the MyOme Personal Genome Test
